Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 259

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 259
---
 kits of Tisseel of the 4 ml Tisseel kit, or 200 kits of          
 Tisseel the 10 ml Tisseel kits per year at a fixed purchase price of $0.136 per unit. The payments under the Supply Agreement are         
 due 30 days from the date of invoice and the Company is subject to a service charge of 1% per month on all amounts past due.              |

The Supply Agreement had an initial term
of 3 years which ended on April 1, 2011; however, the Supply Agreement has an ever-green clause and is automatically renewable for consecutive
1 year terms unless either party gives notice of termination at least 3 months prior to the then current term. The Supply Agreement may
be terminated without cause by Baxter upon 90 days’ prior written notice to the other parties. In addition, either party may terminate
the Supply Agreement in the event of an uncured material breach or insolvency.

| 4. | In March 2019, the Company participated in                                                                                              
 the Horizon 2020 Research and Innovation Framework Programme from European Union through the European Commission Executive Agency       
 for Small and Medium-sized Enterprises (the “EASME”) for its participation in research and development activities of                    
 the Company. Pursuant to the participation in the Programme, the EASME will fund R&D expenses up to total approved budget of            
 approximately $2,680 (EURO 2,185 thousand), out of which $1,095 (EURO 983 thousand) was received in 2019 and $1,039 (EURO 874 thousand) 
 was received in 2021. As of December 31, 2023, the Company, recorded the amount received as a grant liability in other accounts payable 
 in balance sheets.                                                                                                                      
 In April 2024, the Company submitted the                                                                                                
 final report to the Programme and received a notification that the Programme was completed and also received the remaining grant        
 funds at the amount of approximately $350 (EURO 327 thousands). Following the completion of the Programme, the Company recorded all     
 of the grant amount received as a reduction in research and development expenses.                                                       |

| 5. | In January 2024, the Company                                                                                                            
 renewed its facility lease agreement until December 2024. The monthly rental obligations under non-cancellable leases are approximately 
 $5.5 (including $3 for administrative expenses).                                                                                        |

As part of the agreement, the Company
has provided the